801 related articles for article (PubMed ID: 33331305)
21. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Oga T; Chin K; Nagai S; Mimori T; Mishima M
Respir Med; 2011 Sep; 105(9):1380-7. PubMed ID: 21632230
[TBL] [Abstract][Full Text] [Related]
22. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
[TBL] [Abstract][Full Text] [Related]
23. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
[TBL] [Abstract][Full Text] [Related]
24. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
Front Immunol; 2022; 13():879266. PubMed ID: 35603153
[TBL] [Abstract][Full Text] [Related]
25. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
Hoshino K; Muro Y; Sugiura K; Tomita Y; Nakashima R; Mimori T
Rheumatology (Oxford); 2010 Sep; 49(9):1726-33. PubMed ID: 20501546
[TBL] [Abstract][Full Text] [Related]
26. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of idiopathic inflammatory myopathies with novel myositis-specific autoantibodies.
Rams A; Kosałka-Węgiel J; Kuszmiersz P; Matyja-Bednarczyk A; Polański S; Zaręba L; Bazan-Socha S
Adv Clin Exp Med; 2021 Dec; 30(12):1239-1248. PubMed ID: 34610217
[TBL] [Abstract][Full Text] [Related]
28. Characterization of Patients With Dermatomyositis According to Anti-Melanoma Differentiation-Associated Gene-5 Autoantibodies in Centers from 3 Latin American Countries: A Cohort Study.
Olivo Pallo PA; Hoff LS; Borges IBP; Torres-Ruiz J; Cassiano-Quezada F; Granel A; Gomez G; Pisoni C; Gomez R; Shinjo SK
J Clin Rheumatol; 2022 Mar; 28(2):e444-e448. PubMed ID: 34262005
[TBL] [Abstract][Full Text] [Related]
29. Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody.
Hosono Y; Nakashima R; Serada S; Murakami K; Imura Y; Yoshifuji H; Ohmura K; Naka T; Mimori T
J Autoimmun; 2017 Feb; 77():116-122. PubMed ID: 27919567
[TBL] [Abstract][Full Text] [Related]
30. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis.
Mukae H; Ishimoto H; Sakamoto N; Hara S; Kakugawa T; Nakayama S; Ishimatsu Y; Kawakami A; Eguchi K; Kohno S
Chest; 2009 Nov; 136(5):1341-1347. PubMed ID: 19581351
[TBL] [Abstract][Full Text] [Related]
31. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis.
Labrador-Horrillo M; Martinez MA; Selva-O'Callaghan A; Trallero-Araguas E; Balada E; Vilardell-Tarres M; Juárez C
J Immunol Res; 2014; 2014():290797. PubMed ID: 24741583
[TBL] [Abstract][Full Text] [Related]
32. Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases.
Fujisawa T; Hozumi H; Kono M; Enomoto N; Nakamura Y; Inui N; Nakashima R; Imura Y; Mimori T; Suda T
Respir Investig; 2017 Mar; 55(2):130-137. PubMed ID: 28274528
[TBL] [Abstract][Full Text] [Related]
33. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease.
Gui X; Shenyun S; Ding H; Wang R; Tong J; Yu M; Zhao T; Ma M; Ding J; Xin X; Qiu Y; Qiu X; Zhang Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
Rheumatology (Oxford); 2022 Nov; 61(11):4570-4578. PubMed ID: 35148366
[TBL] [Abstract][Full Text] [Related]
34. Disease characteristics and clinical outcomes of adults and children with anti-MDA-5 antibody-associated myositis: a prospective observational bicentric study.
Dunga SK; Kavadichanda C; Gupta L; Naveen R; Agarwal V; Negi VS
Rheumatol Int; 2022 Jul; 42(7):1155-1165. PubMed ID: 34050793
[TBL] [Abstract][Full Text] [Related]
35. [Clinical and immunological characteristics of myositis complicated with thromboembolism].
Zhu FY; Xing XY; Tang XF; Li YM; Shao M; Zhang XW; Li YH; Sun XL; He J
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):995-1000. PubMed ID: 33331304
[TBL] [Abstract][Full Text] [Related]
36. Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti-MDA5 antibody-positive dermatomyositis related interstitial lung disease.
Li Y; Liu X; Tian M; Zou R; Gao Y; Huang M; Zhou K; Cao M; Cai H
Clin Respir J; 2023 Jun; 17(6):507-515. PubMed ID: 37041007
[TBL] [Abstract][Full Text] [Related]
37. Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease.
Sasaki N; Ishii A; Kurabayashi T; Sugiyama M; Izumi Y; Nakagome Y; Hirano K; Sasaki S; Kondo Y; Nogi S; Nishikawa A; Hosono Y; Yamada C; Sato S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):87-94. PubMed ID: 33048020
[TBL] [Abstract][Full Text] [Related]
38. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
[TBL] [Abstract][Full Text] [Related]
39. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies.
Sato S; Kuwana M; Fujita T; Suzuki Y
Mod Rheumatol; 2012 Aug; 22(4):625-9. PubMed ID: 22124544
[TBL] [Abstract][Full Text] [Related]
40. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
